Generate Biomedicines and Zealand Pharma have entered a collaboration to develop multispecific protein therapeutics for obesity and metabolic diseases using AI-driven design. Generate will lead research with its generative AI platform, receiving $30 million upfront and up to nearly $1.2 billion in milestones, while Zealand Pharma will handle clinical development and commercialization. This partnership combines Zealand's metabolic expertise with Generate's AI capabilities to accelerate new treatments beyond peptides, potentially expanding to a third program. The collaboration aims to address unmet medical needs in cardiometabolic health with innovative protein-based drugs.
The collaboration between Generate Biomedicines and Zealand Pharma on AI-engineered protein therapeutics for metabolic diseases is presented here with Pluang's Health-sector market data as context. As of Oct 14, 2026 03:02 WIB, out of 128 priced US Health-sector stocks, 28 rose and 100 fell. Among notable movers, TXG traded at USD 71.71 with a 4.63% decline and full buy-side order activity, ERAS at USD 14.78 dropped 4.40% with all sell orders, and VRTX at USD 485.08 fell 4.32% with a nearly even buy/sell split and the longest typical hold time of 120 days on Pluang.
Applied Materials projects sustained demand for its chipmaking equipment driven by AI infrastructure growth, expecting faster spending on wafer fab equipment through 2030. The company aims to increase its market share by over 2 percentage points from...
Gordon Haskett Capital Corporation set a $105 price target for Ollie's Bargain Outlet, suggesting an 18.1% upside from its current price around $89. The company’s board approved an additional $500 million share repurchase authorization, increasing to...
FRUIT Holdings, Inc. introduced PAVE, a new protocol designed to allow AI systems to call on human judgment and authority when needed. This approach ensures that human input retains its value, authority, and attribution within AI workflows, addressin...
AngioDynamics reported a 6.9% revenue increase to $80.9 million and a narrowed adjusted loss of 4 cents per share for Q1 fiscal 2027, with strong Med Tech sales growing 13.2%. Despite beating earnings expectations and improved gross margin, the stock...
Nathan's Famous, Inc. is proposed to be sold to Smithfield Foods, Inc. with shareholders set to receive $102 in cash per share. The law firm Kahn Swick & Foti, led by former Louisiana Attorney General Charles C. Foti, Jr., is investigating whether th...
